Nuovi test in competizione con il PSA per la diagnosi di carcinoma prostatico
Abstract
Alternative tests to PSA for prostate cancer diagnosis Prostate specific antigen (PSA) is still the most useful tool to select the population requiring prostate biopsy. The main downsides of PSA are an inadequate sensitivity to be used in screening and a low specificity for cancer detection. So far, a limited value for PSA derivates (velocity, density, free, proisoforms and doubling time) has been recognised. We present a short review of the literature describing a selection of the most promising alternatives to PSA being studied currently: PCA3, serum kallikreins, serum detectable prostate specific membrane antigen, the nuclear matrix protein EPCA, EPCA-2, prostatic acid phosphatase, urine detectable GSTP1, anti-AMACR antibodies, sarcosine, plasminogen activating urokinase, IGFBP, TGF beta 1, PSP94, IL6, plasmatic DNA, serum autoantibodies, neuroendocrine markers, proteomic analysis.
Urologia 2011; 78(2): 75 - 81
Article Type: REVIEW
DOI:10.5301/RU.2011.7973
Authors
Elio Defilippi, Andrea Zitella, Alessandro Tizzani
Article History
- • Accepted on 26/12/2010
- • Available online on 28/04/2011
This article is available as full text PDF.
Authors
- Defilippi, Elio
[PubMed]
[Google Scholar]
Struttura complessa ospedaliero-universitaria, Urologia 1, Ospedale S. Giovanni Battista, Torino - Italy
- Zitella, Andrea [PubMed] [Google Scholar]
- Tizzani, Alessandro
[PubMed]
[Google Scholar]
Struttura complessa ospedaliero-universitaria, Urologia 1, Ospedale S. Giovanni Battista, Torino - Italy
Article usage statistics
The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.